Results of CD95-Dependent Apoptosis in LGL Leukemia
| CD3+ LGL Leukemia (patient no.) . | % Specific Cell Death After Anti-CD95 MoAb Exposure . | |
|---|---|---|
| Freshly Isolated . | Post-PHA/IL-2 . | |
| 1 | 34 | 50 |
| 2 | <5 | 33 |
| 3 | <5 | 56 |
| 4 | <5 | 43 |
| 5 | <5 | 53 |
| 6 | <5 | 53 |
| 7 | <5 | 57 |
| 8 | <5 | 30 |
| 9 | <5 | 45 |
| 10 | <5 | <5 |
| 11 | <5 | 76 |
| CD3+ LGL Leukemia (patient no.) . | % Specific Cell Death After Anti-CD95 MoAb Exposure . | |
|---|---|---|
| Freshly Isolated . | Post-PHA/IL-2 . | |
| 1 | 34 | 50 |
| 2 | <5 | 33 |
| 3 | <5 | 56 |
| 4 | <5 | 43 |
| 5 | <5 | 53 |
| 6 | <5 | 53 |
| 7 | <5 | 57 |
| 8 | <5 | 30 |
| 9 | <5 | 45 |
| 10 | <5 | <5 |
| 11 | <5 | 76 |
Percentage of specific cell death was calculated as described in the Patients and Methods. Anti-CD95 MoAb was added for 24 hours. As positive controls for apoptosis assays, CEM cell line and normal activated T cells were used. For CEM, apoptosis was 60% ± 5% (n = 5). For normal activated T cells, 50% ± 15% cell death was observed (n = 5).